πŸ‡ΊπŸ‡Έ FDA
Patent

US 12378245

Crystalline forms of an RSK inhibitor

granted A61PA61P35/00

Quick answer

US patent 12378245 (Crystalline forms of an RSK inhibitor) held by PHOENIX MOLECULAR DESIGNS expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PHOENIX MOLECULAR DESIGNS
Grant date
Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61P, A61P35/00